Ono Pharmaceutical (OTCMKTS:OPHLF – Get Free Report) and VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.
Institutional and Insider Ownership
83.8% of VYNE Therapeutics shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Ono Pharmaceutical and VYNE Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ono Pharmaceutical | $3.20 billion | 2.06 | $330.31 million | $0.70 | 20.00 |
| VYNE Therapeutics | $500,000.00 | 37.93 | -$39.83 million | ($0.78) | -0.73 |
Ono Pharmaceutical has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Ono Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Ono Pharmaceutical and VYNE Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ono Pharmaceutical | 0 | 0 | 0 | 0 | 0.00 |
| VYNE Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
VYNE Therapeutics has a consensus target price of $4.50, indicating a potential upside of 689.89%. Given VYNE Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe VYNE Therapeutics is more favorable than Ono Pharmaceutical.
Risk & Volatility
Ono Pharmaceutical has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.
Profitability
This table compares Ono Pharmaceutical and VYNE Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ono Pharmaceutical | 9.75% | 6.13% | 4.64% |
| VYNE Therapeutics | -6,425.19% | -80.84% | -66.20% |
Summary
Ono Pharmaceutical beats VYNE Therapeutics on 7 of the 13 factors compared between the two stocks.
About Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
